PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using PI-2620

Eligibility Criteria

• 1. Male or female ≥ 45 years of age currently enrolled in UNICORN (IRB #842873)
• 2. If female, post-menopausal or surgically sterile (i.e., unable to have children due to hysterectomy, removal of the Fallopian tubes, tubal ligation, or similar surgery).
• 3. Cognitively and neurologically normal according to one of the following criteria:
• 4. Not clinically depressed, according to one of the following criteria:
• 5. No history of early-onset neurodegenerative disease in biological siblings or parents, based on the investigators' assessment of the participant's self-reported history.
• 1. Male or female ≥ 45 years of age currently enrolled in UNICORN (IRB #842873)
• 2. If female, post-menopausal or surgically sterile (i.e., unable to have children due to hysterectomy, removal of the Fallopian tubes, tubal ligation, or similar surgery).
• 3. Clinically diagnosed by a trained clinician as having logopenic-variant primary progressive aphasia (lvPPA) or posterior cortical atrophy (PCA).
• 4. Not clinically depressed, according to one of the following criteria:
• 5. Have a study partner or legally authorized representative who can accompany the participant for all screening and study activities.
• 3. Group 3: FTLD due to tau (FTLD-tau, n=12)
• 1. Male or female ≥ 45 years of age currently enrolled in UNICORN (IRB #842873)
• 2. If female, post-menopausal or surgically sterile. (i.e., unable to have children due to hysterectomy, removal of the Fallopian tubes, tubal ligation, or similar surgery).
• 3. Clinically diagnosed by a trained clinician as having progressive supranuclear palsy (PSP), non-fluent agrammatic primary progressive aphasia (naPPA), or behavioral-variant frontotemporal dementia (bvFTD) consistent with Pick's disease.
• 4. Not clinically depressed, according to one of the following criteria:
• 5. Have a study partner or legally authorized representative who can accompany the participant for all screening and study activities.
• 4. Group 4: FTLD due to TDP-43 (FTLD-TDP, n=12)
• 1. Male or female ≥ 45 years of age currently enrolled in UNICORN (IRB #842873)
• 2. If female, post-menopausal or surgically sterile (i.e., unable to have children due to hysterectomy, removal of the Fallopian tubes, tubal ligation, or similar surgery).
• 3. Clinically diagnosed by a trained clinician as having amyotropic lateral sclerosis with frontotemporal dementia (ALS-FTD) or semantic-variant primary progressive aphasia (svPPA).
• 4. Not clinically depressed, according to one of the following criteria:
• 5. Have a study partner or legally authorized representative who can accompany the participant for all screening and study activities.
• 5. Group 5: FTLD-tau due to a known genetic mutation (genetic FTLD-tau, n=3)
• 1. Male or female ≥ 45 years of age
• 2. Currently enrolled in UNICORN (IRB #842873) with a genetic test result indicating a mutation in the MAPT gene.
• 3. If female, post-menopausal or surgically sterile (i.e., unable to have children due to hysterectomy, removal of the Fallopian tubes, tubal ligation, or similar surgery).
• 4. Clinically diagnosed by a trained clinician as having progressive supranuclear palsy (PSP), non-fluent agrammatic primary progressive aphasia (naPPA), or behavioral-variant frontotemporal dementia (bvFTD) consistent with Pick's disease.
• 5. Not clinically depressed, according to one of the following criteria:
• 6. Have a study partner or legally authorized representative who can accompany the participant for all screening and study activities.
• 6. Group 6: FTLD-TDP due to a known genetic mutation (genetic FTLD-TDP, n=3)
• 1. Male or female ≥ 45 years of age
• 2. Currently enrolled in UNICORN (IRB #842873) with a genetic test result indicating a mutation in the GRN gene or in open reading frame 72 of chromosome 9 (C9orf72).
• 3. If female, post-menopausal or surgically sterile (i.e., unable to have children due to hysterectomy, removal of the Fallopian tubes, tubal ligation, or similar surgery).
• 4. Clinically diagnosed by a trained clinician as having amyotropic lateral sclerosis with frontotemporal dementia (ALS-FTD) or semantic-variant primary progressive aphasia (svPPA)
• 5. Not clinically depressed, according to one of the following criteria:
• 6. Have a study partner or legally authorized representative who can accompany the participant for all screening and study activities.
• 7. Group 7: amnestic Alzheimer's disease (naAD, n=15)
• 1. Male or female ≥ 45 years of age currently enrolled in UNICORN (IRB #842873) 2. If female, post-menopausal or surgically sterile (i.e., unable to have children due to hysterectomy, removal of the Fallopian tubes, tubal ligation, or similar surgery).
• 3. Clinically diagnosed by a trained clinician as having amnestic mild cognitive impairment (MCI) or amnestic Alzheimer's disease (aAD).
• 4. Not clinically depressed, according to one of the following criteria: i. Geriatric Depression scale ≤ 6 (assessed ≤ 6 months prior to study enrollment), OR ii. Evaluation by a trained clinician 5. Have a study partner or legally authorized representative who can accompany the participant for all screening and study activities.
• 1. The participant has any medical or psychiatric conditions that, in the opinion of the investigator, would compromise the participant's safety or successful participation in the study.
• 2. The investigators of UNICORN (IRB #842873) have determined the participant has evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with analysis of the PET scan.
• 3. The participant is unable to tolerate or have a contraindication to imaging procedures in the opinion of an investigator.
• 4. The participant has a history of significant or ongoing alcohol abuse or substance abuse, or dependence based on medical record review or self-reported.
• 5. The participant is enrolled in a clinical trial for a disease-modifying treatment that targets the molecular pathology underlying their neurodegenerative disease.